2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Kenvue company profile · consumer health (Tylenol, Band-Aid, Neutrogena, Listerine, Aveeno) · history · financial snapshot · S&P 500 rank #284 · 肯悅公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | KVUE (NYSE) |
| Company | Kenvue Inc. |
| GICS sector / industry | Consumer Staples (XLP) / Personal Care Products |
| S&P 500 rank (by weight) | #284 · 0.05% (Oct 30, 2026) |
| Sector rank (by market cap) | #17 in Consumer Staples (Oct 30, 2026) |
| Share price (frozen benchmark) | $19.31 (Oct 30, 2026) |
| Headquarters | Summit, New Jersey |
| Founded | 2023 (spun off from Johnson & Johnson) |
| CEO | Kirk Perry (CEO, per the Feb 17, 2026 results release) |
| Employees | about 22,000 (2026 profile) |
| Market cap | $37.11B (Oct 30, 2026) |
WHAT IT DOES
Kenvue is the consumer health company spun off from Johnson & Johnson in 2023, owning brands including Tylenol, Band-Aid, Neutrogena, Listerine, Aveeno, Johnson's Baby and Nicorette, sold in pharmacies, supermarkets and online in more than 165 countries. It is the world's largest pure-play consumer health company by revenue.
The model is brand plus shelf: trusted names command premium prices and prime retail placement, and the portfolio spans self care, skin health and essential health. FY2025 net sales were $15.124B, down 2.1% from $15.455B (organic −2.2%), operating income was $2.414B, net income was $1.470B, diluted EPS was $0.76 and adjusted diluted EPS was $1.08.
Two overhangs define the story: talc litigation inherited from Johnson & Johnson, and a pending Kimberly-Clark transaction — the company stated it would not provide forward-looking guidance due to the pending transaction.
BUSINESS SEGMENTS — FY2025
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| Self Care | $6,378M | — | -2.3% |
| Skin Health and Beauty | $4,114M | — | -3.0% |
| Essential Health | $4,632M | — | -1.2% |
HISTORY
| Year | Milestone |
|---|---|
| 2023 | Spun off from Johnson & Johnson; initial public offering on the New York Stock Exchange |
| 2023 | Shares begin trading as Kenvue, the world's largest pure-play consumer health company |
| 2024 | Portfolio reshaping: divestitures and brand investments under a new strategy |
| 2025 | FY2025 net sales reach $15.124B, with net income of $1.470B; Kimberly-Clark transaction pending |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Net sales | $15.124B (−2.1% YoY; organic −2.2%) |
| Operating income | $2.414B |
| Net income | $1.470B |
| Diluted EPS / Adjusted diluted EPS | $0.76 / $1.08 |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Kenvue is the S&P 500's consumer health name: at a 0.05% index weight and #17 in Consumer Staples by market cap, it is the index's main exposure to over-the-counter health and personal care.
Its brand volumes and organic growth are a standing read on the health consumer — self-care spending moves before broader staples data does.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close) and Slickcharts S&P 500 analysis page (market cap) |
| Financials | Kenvue FY2025 results (fiscal year ended Dec 28, 2025), 10-K filed Feb 20, 2026, company profile sources |
| Sector classification | GICS (Personal Care Products) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | KVUE(NYSE) |
| 公司 | Kenvue Inc. |
| GICS 板塊/行業 | 必需消費品(XLP)/個人護理產品 |
| 標普500排名(按權重) | #284 · 0.05%(2026 年 10 月 30 日) |
| 板塊內排名(按市值) | 必需消費品第 #17(2026 年 10 月 30 日) |
| 股價(凍結基準) | $19.31(2026 年 10 月 30 日) |
| 總部 | 美國新澤西州薩米特 |
| 成立 | 2023 年(自強生分拆) |
| 行政總裁 | Kirk Perry(行政總裁,按 2026 年 2 月 17 日業績公告) |
| 員工 | 約 22,000(2026 年簡介) |
| 市值 | $37.11B(2026 年 10 月 30 日) |
業務概覽
肯悅是 2023 年自強生分拆的消費保健公司,品牌包括 Tylenol、Band-Aid、Neutrogena、Listerine、Aveeno、強生嬰兒與 Nicorette,在 165 多個國家於藥房、超市與線上銷售;按收入為全球最大的純消費保健公司。
其模式為品牌加貨架:受信賴的品牌享有溢價與黃金零售位置,組合涵蓋自我護理、皮膚健康與基本健康。FY2025 淨銷售額為 $15.124B,同比下跌 2.1%(FY2024 為 $15.455B;有機 −2.2%),營業利潤為 $2.414B,淨利潤為 $1.470B,攤薄每股收益為 $0.76,經調整攤薄每股收益為 $1.08。
兩個陰影定義故事:自強生繼承的滑石粉訴訟,以及待定的金佰利交易——公司表示因交易待定而不提供前瞻指引。
業務板塊 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 自我護理 | $6,378M | — | -2.3% |
| 皮膚健康與美容 | $4,114M | — | -3.0% |
| 基本健康 | $4,632M | — | -1.2% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 2023 | 自強生分拆;在紐約證券交易所首次公開招股 |
| 2023 | 以肯悅名義開始交易,為全球最大的純消費保健公司 |
| 2024 | 組合重塑:新戰略下的資產出售與品牌投資 |
| 2025 | FY2025 淨銷售額達 $15.124B,淨利潤為 $1.470B;金佰利交易待定 |
競爭地位
財務快照 — FY2025
| 淨銷售額 | $15.124B(同比 −2.1%;有機 −2.2%) |
| 營業利潤 | $2.414B |
| 淨利潤 | $1.470B |
| 攤薄每股收益/經調整攤薄每股收益 | $0.76/$1.08 |
主要風險
對標普500的重要性
肯悅是標普500的消費保健標的:指數權重 0.05%、必需消費品板塊市值第 #17,是指數對非處方保健與個人護理的主要敞口。
其品牌銷量與有機增長,是保健消費者的常設讀數——自我護理開支往往先於更廣泛的必需品數據變動。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤)及 Slickcharts 標普500分析頁(市值) |
| 財務 | 肯悅 FY2025 業績(財政年度截至 2025 年 12 月 28 日)、2026 年 2 月 20 日提交的 10-K、公司簡介來源 |
| 板塊分類 | GICS(個人護理產品),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-01 20:35 · updated 2026-11-15 03:31 · rev 7